11/14
06:30 pm
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $55.00 price target on the stock.
11/13
08:00 am
crvo
CervoMed Announces Key Senior Leadership Appointments
Medium
Report
CervoMed Announces Key Senior Leadership Appointments
11/12
07:00 am
crvo
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Low
Report
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
11/8
09:55 am
crvo
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
Low
Report
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
11/7
08:30 am
crvo
CervoMed to Participate in Upcoming Investor Conferences
Medium
Report
CervoMed to Participate in Upcoming Investor Conferences
11/4
08:00 am
crvo
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
High
Report
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
10/29
08:00 am
crvo
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Low
Report
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
10/15
08:00 am
crvo
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
Low
Report
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
10/2
08:00 am
crvo
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Medium
Report
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
9/26
08:00 am
crvo
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
High
Report
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
9/18
08:12 am
crvo
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $55.00 price target on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $55.00 price target on the stock.
8/27
08:30 am
crvo
CervoMed to Participate in Upcoming Investor Conferences
Medium
Report
CervoMed to Participate in Upcoming Investor Conferences